We're pushing the boundaries of science with the hope and expectation that the medicines and vaccines we invent will lead to better health for generations to come.
MSD is inventing new ways to treat cancer.
As part of our focus on cancer, we are committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry. We are currently executing an expansive research program evaluating our anti-PD-1* therapy for a variety of tumors.
Belgium is part of this research with currently 34 clinical studies in different types of cancer (as of 04/2019).
*anti-Programmed Death-1
For more than 100 years, MSD has been discovering and developing vaccines to help protect children, adolescents, and adults from a number of serious diseases.
In Belgium & Luxembourg, our whole portfolio includes vaccines for the prevention of measles, mumps, rubella, chicken pox, human papilloma viruses (HPV), Hepatitis A, Hepatitis B, pneumococcal infections, shingles (herpes zoster), rotavirus and varicella.
We are doing intensive research to improve the understanding of Alzheimer's, a disease which robs more and more people every year of their memory and identity.
MSD is dedicated to further evaluating treatments for Alzheimer's disease and to applying and sharing the deep learning from our clinical trials.
MSD invests heavily in research and is engaged in patient support. We as MSD Belgium delivered E-learnings, courses and continuous education at key moments throughout the year. We provide these services to health care providers so they can gain a better understanding in a complex disease, which diabetes is. In the end only one goal remains: improving the lives of patients living with diabetes.
MSD has a broad portfolio of medicinal products to fight infectious diseases, including HIV/AIDS*, Hepatitis C and invasive fungal diseases. MSD is one of the few companies that continue to invest in antibiotics research. In 2016, MSD pledged its commitment to combating antimicrobial resistance by signing the “Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries” at the World Economic Forum in Davos.
*Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
MSD is supporting the expansion of Project ECHO to improve access to specialty care for diseases such as hepatitis C, HIV, tuberculosis, diabetes, and mental health conditions in underserved communities in India and Vietnam.
MSD for Mothers is the company’s 10-year, $500 million initiative focused on improving the health and well-being of mothers during pregnancy and childbirth.
Over more than a century, MSD has been able to save and improve lives of many patients and their families. Every day, our team strives to make a difference for many people in Belgium and Luxembourg and we do so by developing and offering medicines against cancer, diabetes and infectious diseases. Also, our broad portfolio of vaccines can prevent serious diseases such as measles or HPV related infections.
Brecht Vanneste, Managing Director MSD Belgium & Luxembourg